1. An ambitious usg advanced commitment for subscription-based purchasing of novel antimicrobials and its expected return on investment;Towse,2022
2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis;Murray;Lancet,2022
3. Guidance for demonstrating the societal value of new antibiotics;Simoens;Front Pharmacol,2021
4. Estimating the economic and clinical value of introducing ceftazidime/avibactam into antimicrobial practice in Japan: a dynamic modelling study;Matsumoto;PharmacoEconomics Open,2022
5. Estimating the clinical and economic impact of introducing a new antibacterial into greek clinical practice for the Management of Hospital-Acquired Infections with Limited Treatment Options;Barmpouni;Infect Dis Ther [Internet],2022